Phase II study of pibenzimol in pancreatic cancer - A Southwest Oncology Group study

Investigational New Drugs

Volumn 9, Issue 1, 1991, Pages 95-96

  Kraut, Eric H ^a   Fleming, Tom ^b   Segal, Mark ^c   Neidhart, James A ^d   Behrens, Brent C ^a   MacDonald, John ^e  

^a OHIO STATE UNIVERSITY   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c Columbus CCOP ^*  (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

^e UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

pibenzimol in pancreatic cancer

Indexed keywords

PIBENZIMOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; HUMAN; HYPERGLYCEMIA; INTRAVENOUS DRUG ADMINISTRATION; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; BISBENZIMIDE; DRUG EVALUATION; HUMAN; MIDDLE AGE; PANCREATIC NEOPLASMS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025970948     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/BF00194556     Document Type: Article

References (5)

1. Recent developments in the detection of deoxyribonucleic acid synthesis by 33258-hoechst fluorescense
2. The pleiotropic effects of 33258-hoechst on the cell cycle in Chinese hamster cells in vitro
3. Condensation-inhibition by 33258-hoechst of centromeric heterochromatin in prematurely condensed mouse chromosomes
4. Pattern of condensation of mouse and Chinese hamster chromosomes in G2 and mitosis of 33258-hoechst-treated cells
5. Evaluation of pibenzimol (NCS 322921) in refractory solid malignancies